Benzinga | Aug 28, 2020 07:01AM EDT

Axsome Therapeutics To Present Data From The CONCERT Phase 2 Trial Of AXS-12 in Narcolepsy At The SLEEP 2020 Annual Meeting Aug. 30

NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will present efficacy and safety data from the CONCERT Phase 2 trial of AXS-12 in the treatment of narcolepsy at the 34th Annual SLEEP Meeting of the Associated Professional Sleep Societies (APSS). The meeting, which is a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), is being held virtually from August 27 to 30. AXS-12 is a novel, oral, highly selective and potent norepinephrine reuptake inhibitor for the treatment of narcolepsy. Details of the poster presentation are as follows:

Session: New Treatments for Narcolepsy

Title: Efficacy and Safety of AXS-12 in the Treatment of Narcolepsy: Results from a Phase 2, Double-Blind, Placebo-Controlled, Crossover Trial

Poster Number: 0739

Date: Friday August 28 -- Sunday August 30, 2020

A copy of the presentation will be available shortly after the meeting on Axsome's website at www.axsome.com.